Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.200-1.346 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $52.1 billion-$54.5 billion, compared to the consensus revenue estimate of $52.1 billion.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BAYRY shares. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 3.5%

Shares of BAYRY traded up $0.48 during mid-day trading on Tuesday, reaching $14.05. 259,400 shares of the company were exchanged, compared to its average volume of 1,249,793. The business has a 50 day simple moving average of $12.36 and a two-hundred day simple moving average of $12.08. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. The stock has a market capitalization of $55.22 billion, a PE ratio of -21.95, a PEG ratio of 4.46 and a beta of 0.55. Bayer Aktiengesellschaft has a 52 week low of $7.19 and a 52 week high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, analysts predict that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.